Results 91 to 100 of about 23,377,083 (210)

C-myc and immunoglobulin kappa light chain constant genes are on the 8q+ chromosome of three Burkitt lymphoma lines with t(2;8) translocations [PDF]

open access: yes, 1984
We have determined the localization of c-myc and the immunoglobulin kappa light chain genes on the 8q+/2p- chromosomes of the three Burkitt lymphoma lines BL21, LY66 and LY91 with t(2;8) translocation by in situ hybridization.
Cremer, Thomas   +7 more
core   +1 more source

Differentiation-Inducing Factor-1 Suppresses the Expression of c-Myc in the Human Cancer Cell Lines

open access: yesJournal of Pharmacological Sciences, 2013
Differentiation-inducing factor-1 (DIF-1), a morphogen for Dictyostelium discoideum, inhibits the proliferation of human cancer cell lines by suppressing the Wnt/β-catenin signaling pathway.
Kentaro Jingushi   +7 more
doaj   +1 more source

Overexpression of Cyclin D1 and C-Myc Gene Products in Human Primary Epithelial Ovarian Cancer

open access: yes, 2009
Cyclin D1 and c-Myc are key participants in the cell-cycle pathway, in which aberrancies have been associated with malignant transformation. To date, data on the relationship of expression of these proteins and histologic subtype of epithelial ovarian ...
周松男   +1 more
core  

Additional file 6: of C-Myc-dependent repression of two oncogenic miRNA clusters contributes to triptolide-induced cell death in hepatocellular carcinoma cells

open access: yes, 2018
Figure S4. The overexpression of c-Myc antagonizes triptolide-induced apoptosis in HepG2 cells. Cells were transfected with pcDNA-Mock or pcDNA-c-Myc then treated with triptolide. Cell apoptosis was measured using Annexin-V/PI double staining. (TIFF 735 
Shu-Guang Li (811634)   +8 more
core   +1 more source

Anti-c-myc efficacy block EGFL7 induced prolactinoma tumorigenesis

open access: yesOpen Chemistry, 2019
Resistance to Dopamine agonists therapy is still a key factor that hinders the clinical treatment of prolactinoma. Consequently, a large number of investigations have been carried out to identify novel therapeutic targets.
Lan Xiaolei   +4 more
doaj   +1 more source

Short term effects of c-MYC activation on β-cell physiology and glucose homeostasis in the pIns-c-MycERTAM transgenic mouse [PDF]

open access: yes
Injection of 4-hydroxytamoxifen (4-OHT) activates the oncogene c-myc in transgenic pIns-c-MycERTAM mice, triggering β-cell proliferation in the short term as well as apoptosis and reduced insulin secretion, leading to hyperglycaemia.
Wang, Yi-Fang
core  

Phenotypes of control (c-mycCtrl) and c-myc-deficient embryonic lens (c-mycLe-Cre).

open access: yes, 2014
Phenotypes of control (c-mycCtrl) and c-myc-deficient embryonic lens (c-mycLe-Cre).
Paulo M. G. Rodrigues (439795)   +4 more
core   +1 more source

USP43 stabilizes c-Myc to promote glycolysis and metastasis in bladder cancer

open access: yesCell Death and Disease
A hallmark of tumor cells, including bladder cancer (BLCA) cells, is metabolic reprogramming toward aerobic glycolysis (Warburg effect). The classical oncogene MYC, which is crucial in regulating glycolysis, is amplified and activated in BLCA.
Mingxing Li   +13 more
doaj   +1 more source

c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells

open access: yesBMC Cancer, 2011
Background The BRCA1 gene plays an important role in the maintenance of genomic stability. BRCA1 inactivation contributes to breast cancer tumorigenesis. An increasing number of transcription factors have been shown to regulate BRCA1 expression.
Huo Dezheng   +5 more
doaj   +1 more source

Figures S1-S5 from R1 Regulates Prostate Tumor Growth and Progression By Transcriptional Suppression of the E3 Ligase HUWE1 to Stabilize c-Myc

open access: yes, 2018
Figure S1: R1 does not affect contact inhibition during prostate cancer cell proliferation; Figure S2: R1 does not affect cell apoptosis in prostate cancer cells under both steady state and dynamic conditions; Figure S3: R1 promotes prostate cancer cell ...
Ni Zeng (797786)   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy